Altor BioScience Corporation Launches Its Proprietary IL-15 Superagonist ALT-803 Into Clinical Trials Against Cancer

Published: Aug 15, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics, announced today that the US Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) application for Altor’s novel interleukin-15 (IL-15) superagonist protein complex, ALT-803, against metastatic melanoma. IL-15 is a critical factor for the development, proliferation and activation of cellular immune responses and is considered one of the most promising cancer immunotherapeutic agents by the National Cancer Institute (NCI) of the National Institutes of Health. In preclinical studies, ALT-803 has been shown to have significantly greater biological activity and a longer half-life compared to IL-15. The clinical trial of ALT-803 against incurable melanoma will be jointly sponsored by the Melanoma Research Alliance (MRA), Cancer Immunotherapeutic Trial Network and Altor. Dr. Kim Margolin at the Fred Hutchinson Cancer Research Center at the University of Washington will be the leading Principal Investigator of this first-in-human safety and efficacy clinical trial of ALT-803. Results from this trial will further guide Altor’s development of ALT-803 against other metastatic malignancies and viral infections. Patient enrollment for this trial is expected to start within two months.

Help employers find you! Check out all the jobs and post your resume.

Back to news